Zobrazeno 1 - 10
of 393
pro vyhledávání: '"Michael S, Hofman"'
Autor:
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to n
Externí odkaz:
https://doaj.org/article/b04bf9cbe61641e8b0c83eb5935c6d9f
Autor:
Lachlan McIntosh, Price Jackson, Brittany Emmerson, James P. Buteau, Ramin Alipour, Grace Kong, Michael S. Hofman
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-10 (2024)
Abstract Background Terbium-161 (161Tb)-based radionuclide therapy poses an alternative to current Lutetium-177 (177Lu) approaches with the additional benefit of secondary Auger and conversion electron emissions capable of delivering high doses of lo
Externí odkaz:
https://doaj.org/article/4af472ac353143a988c71298c7ef360f
Autor:
Mark S Stein, Victor Kalff, Scott G Williams, Declan G Murphy, Peter G Colman, Michael S Hofman
Publikováno v:
Endocrine Oncology, Vol 4, Iss 1, Pp 1-7 (2024)
Objectives: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces human prostate cancer incidence, and similar GLP-1 receptor agonists reduce in vitro proliferation and in vivo growth of prostate cancer cell lines. Primary human
Externí odkaz:
https://doaj.org/article/2f51d43b92cc4b87931c1374cc70bebc
Autor:
Brian D. Kelly, Gideon Ptasznik, Matthew J. Roberts, Paul Doan, Phillip Stricker, James Thompson, James Buteau, Kenneth Chen, Omar Alghazo, Jonathan S. O'Brien, Michael S. Hofman, Mark Frydenberg, Nathan Lawrentschuk, Dara Lundon, Declan G. Murphy, Louise Emmett, Daniel Moon
Publikováno v:
European Urology Open Science, Vol 53, Iss , Pp 90-97 (2023)
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect multiparametric magnetic resonance imaging (mpMRI)-invisible prostate tumours and improve the sensitivity of detection of prost
Externí odkaz:
https://doaj.org/article/f90e4b8b3c424e379dd0fe01b30955c7
Autor:
Tsz Him Chan, Annette Haworth, Alan Wang, Mahyar Osanlouy, Scott Williams, Catherine Mitchell, Michael S. Hofman, Rodney J. Hicks, Declan G. Murphy, Hayley M. Reynolds
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Background Prostate-Specific Membrane Antigen (PSMA) PET/CT and multiparametric MRI (mpMRI) are well-established modalities for identifying intra-prostatic lesions (IPLs) in localised prostate cancer. This study aimed to investigate the use
Externí odkaz:
https://doaj.org/article/784a8c82b235496f9ec131a8cf2b4abd
Autor:
Haidar Al Saffar, David C. Chen, Carlos Delgado, Jacob Ingvar, Michael S. Hofman, Nathan Lawrentschuk, Marlon Perera, Declan G. Murphy, Renu Eapen
Publikováno v:
Cancers, Vol 16, Iss 5, p 939 (2024)
The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abiliti
Externí odkaz:
https://doaj.org/article/40aec91725c7462c8220163bbe92e048
Autor:
Ciara Conduit, Thuan Tzen Koh, Michael S Hofman, Guy C Toner, Jeremy Goad, Nathan Lawrentschuk, Keen-Hun Tai, Jeremy H Lewin, Ben Tran
Publikováno v:
Cancer Imaging, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Survivors of testicular cancer may experience long-term morbidity following treatment. There is an unmet need to investigate techniques that can differentiate individuals who need additional therapy from those who do not. 2-18fluo
Externí odkaz:
https://doaj.org/article/0eeadf1443534cc485a6cb545978a500
Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
Autor:
Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Price Jackson, Tomas Kron, Michael S. Hofman, Shankar Siva
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 35, Iss , Pp 84-89 (2022)
Background: Biology-guided radiotherapy (BgRT) delivers dose to tumours triggered from positron emission tomography (PET) detection. Prostate specific membrane antigen (PSMA) PET uptake is abundant in the dominant intraprostatic lesion (DIL). This st
Externí odkaz:
https://doaj.org/article/0df954ce5c524670ac671bddc108ccf3
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
[ 177 Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (P
Externí odkaz:
https://doaj.org/article/de2a86168b5f4b32961414a9a0aa2b51
Autor:
Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James P. Buteau, Declan G. Murphy, Brian Kelly, Lavinia Spain, Shahneen Sandhu, Arun A. Azad, Elizabeth Medhurst, Grace Kong, Michael S. Hofman
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Reported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [ 177 Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on renal tubular cells, r
Externí odkaz:
https://doaj.org/article/d046a9f4e7954988a4fbdf23c77fed17